<unk>  sold under the brand name Adtralza among others, is a human monoclonal antibody used for the treatment of atopic dermatitis.<unk>  targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye.<unk>  was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021.
Tralokinumab
Bezlotoxumab
Ustekinumab
Evolocumab
Alirocumab
Olaratumab
Lanadelumab
Durvalumab